Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Sulsky, R., Magnin, D.R., Huang, Y., Simpkins, L., Taunk, P., Patel, M., Zhu, Y., Stouch, T.R., Bassolino-Klimas, D., Parker, R., Harrity, T., Stoffel, R., Taylor, D.S., Lavoie, T.B., Kish, K., Jacobson, B.L., Sheriff, S., Adam, L.P., Ewing, W.R., Robl, J.A.(2007) Bioorg Med Chem Lett 17: 3511-3515
- PubMed: 17502136 
- DOI: https://doi.org/10.1016/j.bmcl.2006.12.044
- Primary Citation of Related Structures:  
2NNQ - PubMed Abstract: 
Herein we report the first disclosure of biphenyl azoles that are nanomolar binders of adipocyte fatty acid binding protein (aFABP or aP2) with up to thousand-fold selectivity against muscle fatty acid binding protein and epidermal fatty acid binding protein. In addition a new radio-ligand to determine binding against the three fatty acid binding proteins was also synthesized.
Organizational Affiliation: 
Department of Metabolic Disease Chemistry, Bristol Myers-Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543-5400, USA. sulskyr@bms.com